p2IwAF' (wild-type p53-activated fragment 1) is involved in the control of mammalian cell cycle through the binding and inhibition of cyclin-dependent kinases (Cdk). Because the product of WAFl gene is a potent downstream effector of the p53 tumor-suppressor gene function, its pattern of cellular expression might correlate with nuclear accumulation of p53-encoded protein and/or p53 gene mutations occurring in malignant lymphomas. To investigate this issue, we analyzed immunohistochemically the expression of p53 and p2IwAF1 proteins in tissue involved by non-Hodgkin's lymphomas [NHLs; 253 cases) of various histologic types. In a proportion of them (80 cases), we also investigated the possible presence of p53 gene mutations using single-strand conformation polymorphism analysis and direct DNA sequencing. The absence of both p2IwAF' and p53 proteins was observed in 147 of 217 cases (67.79'0) among CD30-NHL and in only 8 of 36 (22. 29'0) CD30' cases, which were mostly HE CONTROL OF mammalian cell cycle involves a family of proteins that bind to and inhibit cyclin-dependent kinases (Cdk). One of the best known of these inhibitors is p21WAF' (wild-type p53-activated fragment 1; also known as Cipl, SDI1, or Pic-l), a small p21-kD protein that is able to affect the function of most known cyclidCdk complexes, blocking DNA replication and cell cycle progression into S phase."' p21WAF' plays a dual cell-cycle inhibitory function at the G1-checkpoint, because it can interact with cyclin/ Cdk complexes and also with the DNA polymerase S replicating factor proliferating-cell nuclear antigen (PCNA), binding the targets with separate domains.'" Evidence has been provided that the WAF1 gene contains p53-binding sites and is transactivated after treatment with DNA-damaging agents and the p21WAF' product is a potent downstream effector of the p53 tumor-suppressor gene function.'.'.'' Although in some normal and neoplastic cells p2lWAF' can be induced by differentiation-related stimuli without the requirement of p53 protein,""3 the expression and function of p21WAF' after genotoxic stress and DNA damage seems to anaplastic large-cell lymphomas. A consistent number (>IO%) of p21wAF'-expressing cells was shown in 48 of 253 (18.99'0) NHL cases, with a higher incidence in CD30' cases (25/36 [69.4%1) , which mostly (21/36) coexpressed p53. These latter cases were characterized by a germline configuration of the p53 gene. In 50 of 253 NHL samples (19.79'0) . 47 of which (21.6%) belong to the CD30-group, neoplastic cells were p53+/p21-. In all of these cases, the p53' cells accounted for more than 50% of neoplastic cells, up t o 1009'0. Point mutations of p53 gene were solely observed in all investigated cases with this latter phenotype. Our findings strongly suggest that the combined immunohistochemical evaluation of p53 and p2IwAF' is a valuable means of assessing the functional status of the p53 tumor-suppressor gene product in NHL with potential application in the monitorage and prognostication of individual cases. 0 1996 by The American Society of Hematology.
be strictly dependent on the presence of functional wild-type
The loss of p53 function due to gene deletions andor point mutations is an extremely common occurrence in human canceris and is relatively frequent in hematologic malignancies, including Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), acute lymphoid and myeloid leukemia, and myelodisplastic syndromes. '6-25 Apart from the obvious interest regarding the pathogenetic significance of p53 gene alterations, there is also evidence of a possible association between abnormalities of p53 function and clinical features such as histologic progression, resistance to chemotherapy, and short survival in some hematologic malignancies, including B-cell chronic lymphocytic leukemia, mucosa-associated lymphoid tissue lymphoma, follicular lymphomas, and mantle cell lymphoma.26-" Several data suggest that p53-dependent apoptosis is a critical regulator of oncogenesis and can modulate the cytotoxicity of anticancer p53 is currently regarded as a potentially important regulator of treatment r e~p o n s e . '~.~~ All of these findings suggest that the analysis of p53 functional status and, in particular, the induction of its functional effector ~2 1~"~' may be important determinants of tumor response in vivo and may provide prognostically useful information in clinical practice. Overexpression of p21 results in growth inhibition of colon cancer cells, brain tumor cells, and leukemia celIs2,'6 and can induce growth arrest and apoptosis of human carcinoma cell lines." The p53 status and the rate of accumulation of p21 are important determinant of both radiosensitivity and chemosensitivity in lymphoid cell lines. and p53 mutations are often associated with decreased sensitivity to DNA-damaging agents."
Overexpression of p53 due to nuclear accumulation has been previously shown in a subset of but only a few data are currently available on the configuration of the WAFl gene and its expression in human malignancies."." In this study, we analyzed p2lWAF1 expression in a large series of low-and high-grade non-Hodgkin's lymphoma (NHL), including CD30+ anaplastic large-cell lymphoma (ALCL), using immunohistochemical techniques and ~2 1~" -specific monoclonal antibodies (MoAbs; clones EAlO and 6B6). To assess the possible correlations existing between the expression of p2lWAF1, the nuclear accumulation of p53 molecules, and the occurrence of p53 gene mutations in neoplastic cells, we analyzed immunohistochemically the expression of these two proteins on seriaYconsecutive sections and studied a consistent proportion of cases for the presence of p53 gene mutations using single-strand conformation polymorphism analysis (SSCP) and direct DNA sequencing.
Our findings show that most cases of NHL expressing both p53 and p21 show the p53 gene in germline configuration. On the other hand, in most cases of NHL harboring p53 point mutations, we observed a characteristic immunophenotypic pattern, with a very high number (up to 100%) of p53' cells lacking p2lWAF1 expression. These data strongly suggest that the combined immunohistochemical evaluation of p53 and p2lWAF1 is a valuable means of assessing the functional status of the p53 tumor-suppressor gene product in lymphomas.
MATERIALS AND METHODS

Sample Composition and Patient Population
Formalin-fixed, paraffin-embedded samples of low-and highgrade NHL (217 cases) and CD30+ ALCL (36 cases) were collected from the files of the Departments of Pathology of Verona University (Verona, Italy) and New York University (New York, NY). The cases were selected to include most recognized entities and on the basis of material available. A larger proportion of high-grade NHL was included to increase the NHL population expected to harbor p53 mutations. All samples were obtained at diagnosis, before any treatment. The cases of NHL were classified according to the REAL Clas~ification~~ (on the basis of morphologic and immunophenotypic features). Normal bone marrow trephine biopsies (22 samples), reactive lymph nodes with nonspecific hyperplasia (10 samples) or granulomatosis (sarcoidosis, 3 samples), and infant thymus (2 samples) were used as controls.
Sample Immunostaining
The immunohistochemical analysis for p53 and p2lWAF1 was performed on formalin-fixed (<24 hours of fixation) paraffin-embedded material as previously described in detail." Briefly, sections were deparaffinized in xylene, rehydrated, washed in phosphate-buffered saline (PBS), immersed in 0.01 mom, citrate buffer, pH 6, and microwaved (for 5 minutes at 750 W three times and 10 minutes at 600 W once). The sections were then kept for 15 minutes at room temperature before further PBS washing and immunostaining. Two different MoAbs recognizing p2IwAF' were used: clone EAlO (Oncogene Science, Uniondale, NY) and clone 6B6 (Pharmingen, San Diego, CA). MoAb DO-1 (Dako, Glostrup, Denmark) was used for detecting p53.
Cells were considered positive only when a distinct nuclear immunostaining could be shown, excluding cells with faint staining. A quantitative evaluation of antigen expression was performed in NHL cases, assigning to each case a different score obtained by evaluating the percentage of positive cells: -, 0% to 10%; +, 10% to 20%; ++, 20% to 50%; +++, 50% to 100%. Double market analysis was used in selected cases to precisely define the nature of p53 and p21 positivity using previously detailed techniques.&."
Polymerase Chain Reaction (PCR)-SSCP Analysis for Detection of p53 Gene Mutations
The presence of mutations in exons 2 through 10 of the p53 gene has been screened in 80 cases using the SSCP analysis of PCRamplified DNA fragments (PCR-SSCP).",47 The 80 samples included 62 B-NHL and 18 CD30' NHL. Frozen tissues were used as the source of DNA.
The sequences of primers used to PCR-amplify different p53 exons were as follows (5'-3'): exons 2-3, TGGATCCTC'ITGCAGCAGCCA and ACCC'ITGTCCTTACC-AGAA; exon 4, TTITCACCCATCTACAGTCC and CTCAGGG-CAACTGACCGTGC; exon 5 , TTCCTC'ITCCTGCAGTACTCC and GCCCCAGCTGCTCACCATCG; exon 6, CGATGGTGAGCA-GCTGGGGC and G'ITGCAAACCAGACCTCA; exon 7, TCCTAGGlTGGCTCTGAC and CAAGTGGCTCCTGACCTGGA; exon 8, CCTATCCTGAGTAGTGGTAA and C C T G C ' I T " A -CCTCGCT; exon 9, TTGCCTCTTTCCTAGCA and CCCAAGOfigonucfeoride primers.
For personal use only. The primers were S'-end-labeled with [y-"P]-ATP as previously described.'x The PCR mixture contained 0.25 pmol each of the labeled primers. 2 nmol each of the four deoxynucleotides, 0.1 p g of genomic sample DNA. and 0.25 U of Taq polymerase in 10 pL of the buffer specified in the Gene Amp kit (Perkin-Elmer Cetus. Norwalk, CT). Thirty cycles of the reaction at 94°C 55°C. and 72°C for 0.5. 0.5. and I minute, respectively, were run in a Thermocycler (Perkin-Elmer Cetus).
A portion of the PCR mixture ( I pL) was withdrawn, mixed with 9 pL of 0.1% NaDodSO, and IO mmol/L EDTA, and analyzed on a 5% acrylamide gel to check the amplification product. Then, 2 p L of this solution was mixed with 2 p L of 95% formamide, 20 mmol/L EDTA. 0.05% bromophenol blue, and 0.05% xylene cyanol: heated at 80°C: and applied ( I pWlane) to a 6% polyacryl-
PCR.
SSCP. To obtain the maximum sensitivity of the SSCP analysis, the samples were also run on two additional 6% polyacrylamide gels.
with the respective addition of 5% and 10% glycerol. The three different types of gels were electrophoresed at 30 W for 2 to 6 hours in two different conditions, the first at room temperature (20°C to 25°C) using a couple of fans for cooling and the second at +4"C in a cold room. The gels were dried on filter paper and exposed to xray film at -80°C for 0.5 to 12 hours with an intensifying screen (DuPont, Dreieich. Germany). Of the different experimental conditions used, the best resolution of normal and shifted bands was usually achieved running the samples in 5% glycerol gels at room temperature.
Direct DNA Sequencing
The DNA samples that showed mobility shifts of single-stranded DNA fragments were subjected to direct sequencing by the asymmetric PCR method, as previously To enrich the mutated sequences. the shifted bands were eluted from the gel, secondarily amplified, and sequenced according to the method described by Su- zuki et d.'" The wild-type bands of the same cases were also sequenced. as an internal control. Briefly. the small area of the gel corresponding to the position of the appropriate band was cut out. immersed in 25 pL of distilled water in a 0.5-mL centrifuge tube and heated at 80°C for IS minutes. The water extract ( 5 pL) was subjected to asymmetric amplification by the PCR (SO cycles) in a mixture (SO pL) containing an uneven molar ratio of the two primers ( IO to SO: 1 ). Asymmetric PCR products were freed of unincorporated nucleotides and primers using a Centricon 30 microconcentrator (Amicon. Beverly. MA) and then subjected to sequencing reaction. After annealing to a 5'4abeled primer. the sequencing reactions were performed using the termination mixtures of a Sequenase kit (US Biochemical Corp. Cleveland. OH) and analyzed on ii 6% polyacrylamide gel containing 7 m o l n urea.
RESULTS
Iinriirrriohisrochernicnl Aiin1y.si.s of p2I "'~"'.' atid 1153 Similar results were obtained in all samples studied using the two different MoAbs specific for p21"'"''' (clones EAIO and 6B6). In control reactive lymph node and infant thymus samples, distinct nuclear immunostaining for p2 I"""' was observed only in rare scattered cells. The positive cells were mainly elongated and spindle-shaped. However, their precise origin could not be recognized with certainty. In granulomatous lymph nodes, a proportion of epithelioid cells and multinucleated macrophages exhibited strong nuclear staining. In bone marrow samples, rare and scattered mononuclear cells and occasional megakaryocytes showed nuclear reactivity. Cells expressing pS3 nuclear immunostaining were extremely rare in all control samples. Expression of p21"'""' was relatively frequent in NHL. because a consistent (> 10%) number of positive cclls could be shown in 48 of 253 cases ( I 8.9%). with higher incidence in CD30' NHL (2Y36 [69.4'7;]). compared with CD30-NHL (23/2 17 [ l0.5%]). To describe more precisely the complex distribution of p2I\"\" and its relationship with pS3 expression. we defined four patterns of staining: type I. characterized by the complete lack of pS3 and p2 I "'\" expression (pW/p21-): type 11. with neoplastic cells expressing comparable proportions of pS3 and p2I"""' (pS3+/p21+): type 111, with neoplastic cells expressing only p21\"A''' but not pS3 was the most common in CD30' NHL, with 21 of 36 (58.3%) cases exhibiting both p2Iw"" and p53 immunoreactivity in a significant proportion of neoplastic cells (Fig 1  and Table I ). Double-marker analysis showed that p53 and p2IWAF' proteins were mostly coexpressed in the same nuclei. The results were similar in CD30' NHL cases exhibiting a T-cell or B-cell phenotype, with a higher figure in non-B non-T (null) cases ( Table I) . The type 111 pattern was extremely rare (8/253). The type IV (p53'/p21-; 19.76%) was observed in 50 NHL cases, primarily comprising highgrade types (Fig 2 and Table I ). This latter pattern, likely corresponding to the overexpression of nonfunctional p53, was rarely observed in low-grade B-cell NHL (small lymphocytic NHL), but never in T-cell types. Notably, higher figures (45.4%) were observed in high-grade cases supervening in the course of low-grade NHL (transformation). Among 1 1 cases of mantle cell NHL, 4 were characterized by type IV immunohistochemical pattern and ali harbored a missense p53 mutation. Interestingly, 3 of these cases had a transformed morphology.
SSCP Molecular Study of p53 Gene Mutations
PCR-SSCP analysis did not show the presence of p53 mutations in any of the studied NHL samples that were immunohistochemically characterized by the type I (23 cases), type I1 (24 cases), or type I11 (3 cases) staining patterns for p53 and p2IWA". Most investigated type I1 cases (14/24) showing a germline p53 gene configuration were found to be CD30' NHL. On the other hand, all but 1 (291 30) type IV (p53'/p2 1 -) sample studied with molecular analysis was shown to harbor p53 gene abnormalities, as shown by the presence of abnormal bands at SSCP analysis of PCR products (Fig 3 and Tables 1 and 2 ). Among these cases, 24 were large-cell NHL (23 B and 1 non-B non-T), 2 were small lymphocytic lymphoma, 2 were Richter transformation of CLL, and 4 cases were mantle cell NHL. Twenty-eight cases showed shifted bands at SSCP analysis and point mutations at exon 4 (2 cases), exon 5 (7 cases), exon 6 (2 cases), exon 7 (8 cases), exon 8 (8 cases), and exon 9 (I case). One sample showed duplication of codons 162, 163, and 164. In a single case of tonsillar centroblastic NHL, no abnormalities could be detected despite a thorough molecular analysis. The SSCP analysis of PCR-amplified exons 2-3 and I O scored negative in all cases.
The characteristics of the p53 mutations detected by SSCP analysis were further examined by direct sequencing of PCRamplified exons. All mutations were represented by single nucleotide changes resulting in missense mutations (Fig 3 and Table 2 ).
Clinical Results
One hundred fifty patients not treated homogeneously were evaluable for treatment outcome analyses. Fifteen patients had low-grade NHL and IO had mantle cell NHL. 
One hundred twenty-five were classified as high-grade NHL (according to the REAL classification). Response to treat-
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DISCUSSION
In this study, we provide evidence that the immunohistochemical analysis of p2llgene-encoded protein p2 lWAF', a universal inhibitor of cyclin kinases,'-' when assessed in combination with p53 immunostaining, can provide information regarding the functional status of the p53 tumor-suppressor gene. This conclusion derives from the combined use of immunohistochemistry and SSCP analysis. Our study indicates that four different phenotypically distinct groups of NHL can be identified on the basis of p21 and p53 pattern of expression, ie, p21-/p53-, p21+/p53+, p21+1p53, and p21-I p53'. In most p21WAF'-positive cases, the number of neoplastic cells expressing nuclear p21WAF' was comparable to that of cells with nuclear p53 immunostaining, and double marker analysis confirmed the colocalization of both p53 and p2lWAF' in the same neoplastic cells. It is possible to speculate that the p2 1 WAF' overexpression observed in neoplastic cells in these cases is a consequence of the physiologic activation of the WAF1 gene, which is a downstream target of p53 phosphoprotein. This hypothesis is supported by the fact that, in all cases of double-negative (type I pattern) and double-positive NHL (type I1 pattern), the p53 gene was found in gerrnline configuration. Notably among these cases were included 14 cases of CD30' NHL, a lymphoma that frequently shows p53 protein overexpression but lacking p53 somatic mutations?' On the other hand, the presence of p53 gene mutations was documented in practically all investigated cases of NHL characterized by the type IV pattern (strong expression of p53 in the majority of cells and complete lack of p21WAF'). These data strongly suggest that the combined analysis of both p53 and p2IWAF' is much more reliable for detecting p53 gene abnormalities associated with the loss of function than the detection of p53 overexpression alone. In fact, although in some cases the accumulation of p53 molecules can be an indicator of p53 gene mutations, the significance and reliability of such a correspondence has For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From been challanged by several studies5' 54 Taking into account the limitation due to cases with p53 gene deletions and frame shift mutations resulting in no expression of the p53 gene,5n,55 the combined immunohistochemical analysis of p53 and p21WAF' on consecutive sections can provide a rapid and low-cost screening analysis of functionally aberrant p53' cases in the diagnostic routine of NHL. In addition, the analysis of p21WAF1, which is a p53-dependent gene, may provide more significant data in cases harboring heterozygous mutations, allowing a more precise evaluation of the p53 functional status.
The wild-type p53 protein has transcriptional activation functions, and its transactivation activity lies in the 40 most "-terminal amino acids.56 The DNA-binding domain involves an evolutionary conserved region spanning amino acids 100 and 300.57-59 Most p53 gene abnormalities detected in our series clustered in hot spots within this latter conformational domain. Thus, as observed in most other human cancers, the loss of p53-transactivating function in NHL is most likely due to a decreased interaction of mutated p53 with the specific target DNA sequences. Accordingly, many mutations occurring in the p53 DNA-binding region are able to indirectly affect its transactivating function.60.6r Interestingly, proteins have been recently identified that interact with this conserved region and are able to regulate the sequencespecific DNA-binding of wild-type p53, thus providing a basis for understanding the functional alterations induced by p53 gene point mutations?' Further studies are needed to ascertain whether the high grade of correspondence observed between p53 mutational status, p53 nuclear accumulation, and lack of p21WAF' expression observed in NHL is a general finding or is related to peculiar features of lymphoid neoplasms. In fact, in pancreatic cancer, p2 1 WAF' expression does not reflect the functional status of p.53." This discrepancy may be related to the phenotypic effects of p53 action, varying in different cell types as well as a result of cellular environmental p53 is a tumor-suppressor gene mediating G1 growth arrest and apoptosis after y-radiation or chemotherapeutic drugs."-" The detection of p53 gene abnormalities is a useful parameter in the evaluation of the biologic features of hematologic neoplasms and has potential prognostic relevance. Finally, the precise characterization of the p53 status may also provide the rationale for testing new therapeutic drugs modulating the function of mutated p53 products or upregulating the physiologic levels of p21 WAF'.b9, 7n The significance of p53 and p21WAF' evaluation in hematologic oncology has received intense scrutiny, and promising data have been recently provided. Accordingly, in different hematologic malignancies, including B-CLL, multiple myeloma, follicular lymphoma, mantle cell lymphoma, adult T-cell leukemid lymphoma, acute leukemias, myelodisplastic syndromes, etc, the presence of p53 gene has been correlated with a more aggressive behavior, clinical progression, histologic transformation, and resistance to chem~therapy.'~.''.~~.~~ Although we could not show in our series of high-grade NHL a statistically significant difference of treatment outcome between patients characterized by immunohistochemical 1-11-111 and IV patterns, the prognostic trend of p53 functional analysis observed in our study warrants further evaluation of' larger groups of patients.
The simple immunohistochemical approach described in this paper provides a rapid and low-cost test to be used in retrospective studies and in the screening of large series of cases. Finally, the combined detection of p21 and p53 may provide a unique phenotypic marker for the staging and monitorage of NHL evolution at different sites and times. 
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